(-)-trans-C75
(Synonyms: (2S,3R)-C75) 目录号 : GC16184An enantiomer of a FASN inhibitor
Cas No.:1234694-22-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(-)-trans-C75 is an enantiomer of C75, a fatty acid synthase (FAS) inhibitor [1][2].
Fatty acid synthase (FAS) catalyzes the reductive synthesis of long-chain fatty acids from acetyl-coenzyme A (acetyl-CoA) and malonyl-CoA. FAS may represent an important link in feeding regulation and may be a potential therapeutic target [1].
C75 is a fatty acid synthase (FAS) inhibitor. (-)-trans-C75 is an enantiomer of C75. In human cancer cells, it also showed significant in vivo antitumor activity, suppressed DNA replication, induced apoptosis [2].
Intraperitoneal (ip) injection of mice with C75 led to a 95% reduction in 14C-acetate incorporation into fatty acids and a 110% increase in the level of hepatic malonyl-CoA. Both systemic and intracerebroventricular treatment of mice with C75 led to inhibition of feeding and dramatic weight loss. In mice, intraperitoneal (ip) injection of mice with C75 led to weight loss in a dose-dependent way, which was due primarily to inhibition of feeding. C75 (15 mg/kg) reduced food intake by more than 90% over the first 24 hours. Forced feeding largely reversed the observed weight loss. C75 also reduced the expression of neuropeptide Y (NPY) in the hypothalamus that control feeding and energy utilization [1].
References:
[1]. Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000 Jun 30;288(5475):2379-81.
[2]. Chakrabarty, K.,Forzato, C.,Nitti, P., et al. The first kinetic enzymatic resolution of methyl ester of C75. Letters in Organic Chemistry, 2010, 7, 245-248.
| Cas No. | 1234694-22-4 | SDF | |
| 别名 | (2S,3R)-C75 | ||
| 化学名 | tetrahydro-4-methylene-2S-octyl-5-oxo-3R-furancarboxylic acid | ||
| Canonical SMILES | CCCCCCCC[C@H](OC1=O)[C@H](C(O)=O)C1=C | ||
| 分子式 | C14H22O4 | 分子量 | 254.3 |
| 溶解度 | ≤10mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9324 mL | 19.6618 mL | 39.3236 mL |
| 5 mM | 0.7865 mL | 3.9324 mL | 7.8647 mL |
| 10 mM | 0.3932 mL | 1.9662 mL | 3.9324 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: ≥97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet